Actelion vs. Torrent: Macitentan Patent Infringement Case Transferred to Camden Division
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Actelion Pharmaceuticals, Ltd. v. Torrent Pharmaceuticals, Ltd. |
| Case Number | 3:24-cv-03990 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | March 19, 2024 – March 28, 2024 9 days (to transfer) |
| Outcome | Procedural Transfer — Litigation Ongoing |
| Patents at Issue | |
| Accused Products | Macitentan 10 mg oral tablets (generic Opsumit®) |
Case Overview
The Parties
⚖️ Plaintiff
Swiss-based biopharmaceutical company and subsidiary of Johnson & Johnson, recognized as a global leader in pulmonary arterial hypertension therapies.
🛡️ Defendant
Indian-headquartered generic pharmaceutical manufacturer. Its U.S. subsidiary, Torrent Pharma, Inc., regularly files ANDAs challenging branded drug patents.
Patents at Issue
This case centers on two significant U.S. patents protecting Macitentan 10 mg oral tablets, a drug used in the treatment of pulmonary arterial hypertension (PAH). These patents protect both the core chemical compound and related formulation/method of use claims.
- • US7094781B2 — Covers core chemical compound claims related to Macitentan’s active molecular structure.
- • US10946015B2 — Covers formulation or method-of-use claims extending Macitentan’s patent protection.
Developing a generic equivalent?
Check if your generic Macitentan might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was transferred — not dismissed, settled, or adjudicated on the merits. The original docket (3:24-cv-03990) was closed upon reassignment to the Camden Division as Case No. 1:24-cv-3990. No damages were awarded, and no injunctive relief was granted or denied at this stage. The underlying infringement claims remain active under the new case number.
Verdict Cause Analysis
The basis of termination is formally recorded as a case transfer, triggered by intra-district divisional reassignment procedures in the District of New Jersey. This transfer reflects a standard intra-district venue reassignment rather than an inter-district transfer, meaning the substantive litigation continues within New Jersey federal court under different divisional assignment.
Legal Significance
While this specific procedural event carries limited direct precedential weight, Actelion’s assertion of both a compound patent (US7094781B2) and a later-issued patent (US10946015B2) reflects a deliberate evergreening or portfolio-stacking approach common in branded pharmaceutical litigation. This case almost certainly arises from Torrent’s ANDA filing with a Paragraph IV certification, alleging that its generic Macitentan product does not infringe Actelion’s listed patents or that those patents are invalid. Actelion’s prompt filing triggers a 30-month stay on FDA approval of Torrent’s ANDA, a significant commercial weapon for branded manufacturers.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in PAH patents
- Understand claim construction patterns for small molecules
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic drug or formulation.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Macitentan compound and formulations
Multi-Patent Strategy
Compound & formulation patents asserted
ANDA Filings
Require Paragraph IV certification strategies
✅ Key Takeaways
Case transferred intra-district from Newark to Camden; substantive litigation continues under Case No. 1:24-cv-3990.
Search related case law →Two patents asserted: US7094781B2 (compound) and US10946015B2 (likely formulation/use) — representing a layered enforcement strategy.
Explore precedents →Frequently Asked Questions
The case involves U.S. Patent Nos. US7094781B2 and US10946015B2, both covering aspects of Macitentan, the active ingredient in Actelion’s PAH drug Opsumit®.
The original docket (3:24-cv-03990) was closed administratively following an intra-district transfer to the Camden Division. Litigation continues under Case No. 1:24-cv-3990.
Under Hatch-Waxman, Actelion’s timely filing likely triggered a 30-month FDA approval stay on Torrent’s ANDA for generic Macitentan, delaying potential market entry pending resolution of the patent dispute.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Federal Court Records
- USPTO Patent Full-Text Database
- FDA Orange Book
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.